FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus; Guidance for Industry” was released on October 2, 2019 and recommends that CTS modify our current HCV reflex testing algorithm to support these best practices. The new algorithm will take effect on April 20, 2020.
Check out the Communication page for the complete details by clicking the link: Communications
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...